QI-019A / Huazhong University of Science and Technology - LARVOL DELTA

First-in-Human in Vivo Generation of CD19/BCMA Dual-Targeting CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma (IMS 2026) - P1 | "QI-019A is an in vivo lentiviral vector built on the ClariT platform, which uses Macroi-293 cells to reduce vector clearance and incorporates a CAR-less strategy to avoid premature expression during packaging... These first - in - human data confirm the feasibility of in vivo CD19/BCMA dual - targeting CAR - T without lymphodepletion in R/R MM. QI - 019A enables a rapid 8 - day screening - to - infusion turnaround and demonstrates favorable early safety, robust expansion, and promising efficacy. Long-term follow-up is ongoing to assess response durability and clinical outcomes."

CAR T-Cell Therapy • First-in-human • IO biomarker • Late-breaking abstract • P1 data • Preclinical • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology